Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
In a nutshell, Amgen claimed other parties could easily use its patents as a roadmap to develop PCSK9 antibodies, without having to carry out a lot of additional testing. Sanofi and Regeneron ...
In a joint statement, Sanofi and Regeneron said they "strongly disagree" with the jury verdict that Amgen's two patents for antibodies targeting PCSK9 are valid, and will appeal. Joseph LaRosa ...
Vectibix, a monoclonal antibody used to treat colon cancer ... UIRF has granted 113 active licenses for these patents. Immunex, a subsidiary of Amgen, also located in Thousand Oaks, California ...
Unique to US Patent Law ... Circuit found the production of monoclonal antibodies routine, and reversed the decision. The gamut of case law from Amgen, Scripps, Glaxo, and Lilly offers a host ...
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback